Tan Ming
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Pathogens. 2021 Dec 19;10(12):1641. doi: 10.3390/pathogens10121641.
Noroviruses are the major viral pathogens causing epidemic and endemic acute gastroenteritis with significant morbidity and mortality. While vaccines against norovirus diseases have been shown to be of high significance, the development of a broadly effective norovirus vaccine remains difficult, owing to the wide genetic and antigenic diversity of noroviruses with multiple co-circulated variants of various genotypes. In addition, the absence of a robust cell culture system, an efficient animal model, and reliable immune markers of norovirus protection for vaccine evaluation further hinders the developmental process. Among the vaccine candidates that are currently under clinical studies, recombinant VP1-based virus-like particles (VLPs) that mimic major antigenic features of noroviruses are the common ones, with proven safety, immunogenicity, and protective efficacy, supporting a high success likelihood of a useful norovirus vaccine. This short article reviews the recent progress in norovirus vaccine development, focusing on those from recent clinical studies, as well as summarizes the barriers that are being encountered in this developmental process and discusses issues of future perspective.
诺如病毒是引起流行性和地方性急性胃肠炎的主要病毒病原体,具有显著的发病率和死亡率。虽然已证明针对诺如病毒疾病的疫苗具有高度重要性,但由于诺如病毒具有广泛的遗传和抗原多样性,多种基因型的变体同时流行,因此开发一种广泛有效的诺如病毒疫苗仍然困难。此外,缺乏强大的细胞培养系统、有效的动物模型以及用于疫苗评估的可靠的诺如病毒保护性免疫标志物,进一步阻碍了开发进程。在目前正在进行临床研究的候选疫苗中,基于重组VP1的病毒样颗粒(VLP)模拟了诺如病毒的主要抗原特征,是常见的候选疫苗,已证明具有安全性、免疫原性和保护效力,这支持了一种有用的诺如病毒疫苗具有很高的成功可能性。这篇短文回顾了诺如病毒疫苗开发的最新进展,重点关注近期临床研究的进展,同时总结了在这一开发过程中遇到的障碍,并讨论了未来展望的问题。